Addressing the unmet need
Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited access options. While not explicit in the DMT criteria wording, changes advocated for by MSNZ […]
Pharmac review – interim report.
Neil Woodhams, President of MSNZ, welcomed the interim findings of the Pharmac Review released last week. The full report can be found here: https://pharmacreview.health.govt.nz › interim-report. The report highlights the problems MSNZ has experienced over many years in its dealings with PHARMAC, over access to world-class treatments for MS. The length of time taken to make […]